Sustainable intensification in Western Kenya: Who will benefit?

Sustainable intensification in agriculture

Etanercept in juvenile idiopathic arthritis: Who will benefit?

Results 262 previously biologic-naive JIA-patients initiated etanercept; 71% female, 18% systemic-onset subtype. Median age at onset 6.9 (IQR 3.6-11.1) years, median followup 35.6 (IQR 17.4-53.6) months. In the long-term, the overall majority responded to etanercept and up to 40% reached inactive disease. Excellent response after 15 months (85 patients, 32%) was associated with low baseline dis...

Who will benefit from tracheostomy ventilation in motor neuron disease?

The decision when to recommend tracheostomy ventilation in motor neuron disease (amyotrophic lateral sclerosis) has always been difficult. At one extreme is the view that when spontaneous ventilation or non-invasive ventilation is inadequate, a tracheostomy will save the patient’s life and lead to prolonged survival. This view has been more widely held in the USA than elsewhere. In the UK, a co...

Screening by Clinical Breast Examination in Western Kenya: Who Comes?

PURPOSE More than 80% of women with breast cancer in Kenya present to medical care with established late-stage disease. We sought to understand why women might not participate in breast cancer screening when it is offered by comparing the views of a cohort of those who attended a screening special event with those of community controls who did not attend. METHODS All residents living close to...

Sustainable process synthesis-intensification